Congress to investigate Wyeth's alleged illegal promotion of drug to African-Americans

About a week ago, I posted a note (here) about a lawsuit that alleges that Wyeth encouraged its sales force to promote Rapamune to doctors practicing heart, lung, liver, pancreas, and islet cell transplants even though the drug was never approved for patients receiving transplants of these organs. Today, Pharmalot is reporting that the House Committee on Oversight & Government Reform has launched an investigation to determine if Wyeth promoted its kidney transplant drug for unaproved uses and, specifically, targeting African-Americans, even though this is a high-risk patient group. For the full story, go here.